Inspire Medical Systems, Inc. (NYSE:INSP) Stock Has Average Price Target of $66.50

Inspire Medical Systems, Inc. (NYSE:INSP) has been assigned a consensus recommendation of “Hold” from the nineteen analysts that are covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a sell recommendation, twelve have assigned a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $67.44.

INSP has been the topic of a number of analyst reports. Stifel Nicolaus upped their target price on shares of Inspire Medical Systems from $75.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, September 11th. Robert W. Baird raised their price target on shares of Inspire Medical Systems from $54.00 to $59.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. UBS Group started coverage on Inspire Medical Systems in a report on Tuesday, July 28th. They set a “sell” rating and a $39.00 price objective on the stock. Zacks Research lowered Inspire Medical Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 22nd. Finally, Evercore set a $54.00 price target on Inspire Medical Systems in a research report on Tuesday, August 4th.

Inspire Medical Systems Price Performance

Shares of INSP stock opened at $70.36 on Thursday. The stock has a market cap of $2.03 billion, a P/E ratio of 15.23, a price-to-earnings-growth ratio of 5.29 and a beta of 0.73. Inspire Medical Systems has a one year low of $38.91 and a one year high of $147.03. The stock has a fifty day moving average price of $63.49 and a 200 day moving average price of $53.72.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The firm had revenue of $200.58 million for the quarter, compared to the consensus estimate of $194.72 million. During the same quarter in the previous year, the company earned $0.45 earnings per share. The business’s revenue was down 7.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Equities research analysts anticipate that Inspire Medical Systems will post 1.24 EPS for the current year.

Insider Transactions at Inspire Medical Systems

In other news, insider Jason Kelly sold 963 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the transaction, the insider directly owned 18,985 shares of the company’s stock, valued at $1,130,556.75. The trade was a 4.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Inspire Medical Systems

A number of hedge funds and other institutional investors have recently bought and sold shares of INSP. Legal & General Group Plc bought a new stake in Inspire Medical Systems during the 2nd quarter worth about $2,732,000. Alberta Investment Management Corp acquired a new stake in Inspire Medical Systems during the 2nd quarter worth $5,483,000. GSA Capital Partners LLP bought a new stake in shares of Inspire Medical Systems during the 2nd quarter valued at $820,000. WINTON GROUP Ltd boosted its position in shares of Inspire Medical Systems by 790.8% in the 2nd quarter. WINTON GROUP Ltd now owns 37,412 shares of the company’s stock worth $1,669,000 after purchasing an additional 33,212 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of Inspire Medical Systems by 66.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 864,395 shares of the company’s stock worth $38,561,000 after purchasing an additional 344,221 shares during the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company focused on developing and commercializing treatments for obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly becomes blocked during sleep. The company’s primary product is the Inspire therapy system, an implantable device designed for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefits from continuous positive airway pressure (CPAP) therapy.

The Inspire system uses an implantable pulse generator, a stimulation lead and a sensing lead.